These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 8962138)

  • 41. Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes.
    Stahnke B; Thepen T; Stöcker M; Rosinke R; Jost E; Fischer R; Tur MK; Barth S
    Mol Cancer Ther; 2008 Sep; 7(9):2924-32. PubMed ID: 18790773
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Selection of tumor-specific internalizing human antibodies from phage libraries.
    Poul MA; Becerril B; Nielsen UB; Morisson P; Marks JD
    J Mol Biol; 2000 Sep; 301(5):1149-61. PubMed ID: 10966812
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Improving antibody affinity by mimicking somatic hypermutation in vitro.
    Chowdhury PS; Pastan I
    Nat Biotechnol; 1999 Jun; 17(6):568-72. PubMed ID: 10385321
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Characterization of human anti-high molecular weight-melanoma-associated antigen single-chain Fv fragments isolated from a phage display antibody library.
    Desai SA; Wang X; Noronha EJ; Kageshita T; Ferrone S
    Cancer Res; 1998 Jun; 58(11):2417-25. PubMed ID: 9622083
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Development of an EGFRvIII specific recombinant antibody.
    Gupta P; Han SY; Holgado-Madruga M; Mitra SS; Li G; Nitta RT; Wong AJ
    BMC Biotechnol; 2010 Oct; 10():72. PubMed ID: 20925961
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Specific targeting of a mutant, activated FGF receptor found in glioblastoma using a monoclonal antibody.
    Hills D; Rowlinson-Busza G; Gullick WJ
    Int J Cancer; 1995 Nov; 63(4):537-43. PubMed ID: 7591264
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Construction of recombinant adenovirus expressing
    Zhang H; Xu J; Cheng Y; Fu S; Liu Y; Hu Y; DU Y; Bao F
    Sheng Wu Gong Cheng Xue Bao; 2022 Sep; 38(9):3551-3562. PubMed ID: 36151821
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Preparation of single chain variable fragment of MG(7) mAb by phage display technology.
    Yu ZC; Ding J; Nie YZ; Fan DM; Zhang XY
    World J Gastroenterol; 2001 Aug; 7(4):510-4. PubMed ID: 11819819
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Construction of anti-B7-H4-scFv library and screening and identification of anti-B7-H4-scFv].
    Shao L; Xu C; Ji H; Mao W; Wang Y; Liu X; Zhu Y
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 Sep; 32(9):1260-6. PubMed ID: 27609584
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Monoclonal antibody against the fusion junction of a deletion-mutant epidermal growth factor receptor.
    Okamoto S; Yoshikawa K; Obata Y; Shibuya M; Aoki S; Yoshida J; Takahashi T
    Br J Cancer; 1996 Jun; 73(11):1366-72. PubMed ID: 8645581
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A novel strategy for engineering of a smart generation of immune ribonucleases against EGFR
    Taghizadegan N; Firoozrai M; Nassiri M; Ariannejad H
    J Cell Physiol; 2021 Jun; 236(6):4303-4312. PubMed ID: 33421131
    [TBL] [Abstract][Full Text] [Related]  

  • 52. EGFR/EGFRvIII-targeted immunotoxin therapy for the treatment of glioblastomas via convection-enhanced delivery.
    Bao X; Pastan I; Bigner DD; Chandramohan V
    Receptors Clin Investig; 2016; 3(4):. PubMed ID: 28286803
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mutant epidermal growth factor receptors as targets for cancer therapy.
    Lorimer IA
    Curr Cancer Drug Targets; 2002 Jun; 2(2):91-102. PubMed ID: 12188912
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma.
    Humphrey PA; Wong AJ; Vogelstein B; Zalutsky MR; Fuller GN; Archer GE; Friedman HS; Kwatra MM; Bigner SH; Bigner DD
    Proc Natl Acad Sci U S A; 1990 Jun; 87(11):4207-11. PubMed ID: 1693434
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Identification of a novel peptide ligand for the cancer-specific receptor mutation EGFRvIII using high-throughput sequencing of phage-selected peptides.
    Mansour S; Adhya I; Lebleu C; Dumpati R; Rehan A; Chall S; Dai J; Errasti G; Delacroix T; Chakrabarti R
    Sci Rep; 2022 Dec; 12(1):20725. PubMed ID: 36456600
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Enhanced cytotoxicity of a
    Masilamani AP; Huber N; Nagl C; Dettmer-Monaco V; Monaco G; Wolf I; Schultze-Seemann S; Taromi S; Gratzke C; Fuchs H; Wolf P
    Front Pharmacol; 2023; 14():1211824. PubMed ID: 37484018
    [TBL] [Abstract][Full Text] [Related]  

  • 57. EGF mutant receptor vIII as a molecular target in cancer therapy.
    Kuan CT; Wikstrand CJ; Bigner DD
    Endocr Relat Cancer; 2001 Jun; 8(2):83-96. PubMed ID: 11397666
    [No Abstract]   [Full Text] [Related]  

  • 58. Genetic modification of mesenchymal stem cells to express a single-chain antibody against EGFRvIII on the cell surface.
    Balyasnikova IV; Franco-Gou R; Mathis JM; Lesniak MS
    J Tissue Eng Regen Med; 2010 Jun; 4(4):247-58. PubMed ID: 19937911
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme.
    Sampson JH; Archer GE; Mitchell DA; Heimberger AB; Herndon JE; Lally-Goss D; McGehee-Norman S; Paolino A; Reardon DA; Friedman AH; Friedman HS; Bigner DD
    Mol Cancer Ther; 2009 Oct; 8(10):2773-9. PubMed ID: 19825799
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Production and introduction of a novel immunotoxin based on engineered RNase A for inducing death to Her1-positive cell lines.
    Forouharmehr A; Nassiri M; Ghovvati Roudsari S; Javadmanesh A
    J Cell Physiol; 2020 May; 235(5):4679-4687. PubMed ID: 31663127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.